Home › Jobs › rezolutebio

Medical Science Liaison / Senior Medical Science Liaison - Oncology / Rare Endocrine Disorders

rezolutebio · Remote (US) · Posted November 3, 2026 (15 days ago)

Apply on rezolutebio’s siteFill the application with AutoFillSee your fit for this role

Job description

Location: Regionally US-Based- Multiple Regions/Positions Open Therapeutic Area: Oncology / Rare Endocrine Disorders

Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. Our lead investigational therapy, RZ358 (ersodetug), is a fully human monoclonal antibody in late-stage clinical development for the treatment of congenital and acquired forms of hyperinsulinism (HI). Rezolute’s mission is to bring hope and meaningful solutions to patients and families affected by rare diseases through scientific innovation, collaboration, and integrity. As part of a newly established Medical Affairs team, the Medical Science Liaison (MSL) serves as a critical scientific bridge between the company and the external healthcare community, supporting scientific engagement and launch readiness ahead of multiple indication launches planned over the next 2–4 years. The MSL is responsible for developing and strengthening professional relationships with medical thought leaders across rare endocrine and oncologic diseases. Through scientific exchange, the MSL provides medical information and clinical/scientific support to advance Rezolute's Medical Affairs objectives. This position requires an individual with established professional and scientific credibility who can effectively engage with global thought leaders and academic centers of excellence. The MSL is expected to represent Rezolute with the highest professional and ethical standards, in accordance with company policies, applicable industry guidelines, and the mission and values of the Medical Affairs organization.

Posting 978bcc5f-bfa7-4e0f-853e-f16453c5364d on lever. Source: the employer’s listing. Valid through December 18, 2026 unless closed earlier.